晚期实体肿瘤-话题@MedSci - williamhill asia

#晚期实体肿瘤#

15篇内容 | 903人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1754584, encodeId=ec781e54584c1, content=<a href='/topic/show?id=627a5982254' target=_blank style='color:#2F92EE;'>#晚期实体肿瘤#</a>, objectTitle=Front Oncol：安罗替尼联合PD-1抑制剂治疗晚期实体肿瘤有效且毒性可控, objectType=article, longId=218379, objectId=64ef2183e9b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=64ef2183e9b4, replyNumber=0, likeNumber=55, createdTime=2022-04-28, rootId=0, userName=30397616, userId=333936755048, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=64ef2183e9b4, moduleTitle=Front Oncol：安罗替尼联合PD-1抑制剂治疗晚期实体肿瘤有效且毒性可控, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=64ef2183e9b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1754583, encodeId=683a1e5458368, content=<a href='/topic/show?id=627a5982254' target=_blank style='color:#2F92EE;'>#晚期实体肿瘤#</a>, objectTitle=Clin Cancer Res：PI3K/mTORC1/2双重抑制剂Gedatolisib联合卡铂和紫杉醇治疗晚期实体肿瘤, objectType=article, longId=215909, objectId=bd1421590942, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bd1421590942, replyNumber=0, likeNumber=59, createdTime=2021-12-01, rootId=0, userName=30397616, userId=333936755048, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bd1421590942, moduleTitle=Clin Cancer Res：PI3K/mTORC1/2双重抑制剂Gedatolisib联合卡铂和紫杉醇治疗晚期实体肿瘤, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=bd1421590942)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1754582, encodeId=043b1e5458264, content=<a href='/topic/show?id=627a5982254' target=_blank style='color:#2F92EE;'>#晚期实体肿瘤#</a>, objectTitle=Clin Cancer Res：Wee1抑制剂Adavosertib(AZD1775)在晚期实体肿瘤患者中的抗肿瘤活性及相关生物标志物, objectType=article, longId=214645, objectId=1284214645f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1284214645f5, replyNumber=0, likeNumber=57, createdTime=2021-09-05, rootId=0, userName=30397616, userId=333936755048, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1284214645f5, moduleTitle=Clin Cancer Res：Wee1抑制剂Adavosertib(AZD1775)在晚期实体肿瘤患者中的抗肿瘤活性及相关生物标志物, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=1284214645f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1754581, encodeId=0fb51e54581ab, content=<a href='/topic/show?id=627a5982254' target=_blank style='color:#2F92EE;'>#晚期实体肿瘤#</a>, objectTitle=Clin cancer res：抗肿瘤坏死因子受体抗体MK-4166治疗晚期实体肿瘤的首次临床试验结果, objectType=article, longId=205186, objectId=c06e2051867a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c06e2051867a, replyNumber=0, likeNumber=53, createdTime=2021-06-11, rootId=0, userName=30397616, userId=333936755048, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c06e2051867a, moduleTitle=Clin cancer res：抗肿瘤坏死因子受体抗体MK-4166治疗晚期实体肿瘤的首次临床试验结果, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=c06e2051867a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1754580, encodeId=25ea1e54580fe, content=<a href='/topic/show?id=627a5982254' target=_blank style='color:#2F92EE;'>#晚期实体肿瘤#</a>, objectTitle=Brit J Cancer：mTORC1/2抑制剂sapanisertib 在肾癌、子宫内膜癌或膀胱癌扩张期晚期实体肿瘤的一期研究, objectType=article, longId=201242, objectId=0c6d2012422b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0c6d2012422b, replyNumber=0, likeNumber=64, createdTime=2021-08-27, rootId=0, userName=30397616, userId=333936755048, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0c6d2012422b, moduleTitle=Brit J Cancer：mTORC1/2抑制剂sapanisertib 在肾癌、子宫内膜癌或膀胱癌扩张期晚期实体肿瘤的一期研究, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=0c6d2012422b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1754579, encodeId=77df1e54579e9, content=<a href='/topic/show?id=627a5982254' target=_blank style='color:#2F92EE;'>#晚期实体肿瘤#</a>, objectTitle=JAMA Oncol：BMS-986156单药或联合纳武单抗治疗晚期实体肿瘤, objectType=article, longId=183395, objectId=5a5318339506, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5a5318339506, replyNumber=0, likeNumber=53, createdTime=2019-12-18, rootId=0, userName=30397616, userId=333936755048, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5a5318339506, moduleTitle=JAMA Oncol：BMS-986156单药或联合纳武单抗治疗晚期实体肿瘤, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=5a5318339506)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1754578, encodeId=5b771e545781b, content=<a href='/topic/show?id=627a5982254' target=_blank style='color:#2F92EE;'>#晚期实体肿瘤#</a>, objectTitle=Lancet oncol：Pegilodecakin联合抗PD-1单克隆抗体是否可为晚期实体肿瘤提供新的治疗机会？, objectType=article, longId=180124, objectId=a26018012453, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a26018012453, replyNumber=0, likeNumber=61, createdTime=2019-10-16, rootId=0, userName=30397616, userId=333936755048, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a26018012453, moduleTitle=Lancet oncol：Pegilodecakin联合抗PD-1单克隆抗体是否可为晚期实体肿瘤提供新的治疗机会？, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=a26018012453)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1754577, encodeId=c6c41e54577d2, content=<a href='/topic/show?id=627a5982254' target=_blank style='color:#2F92EE;'>#晚期实体肿瘤#</a>, objectTitle=CLIN CANCER RES：MEDI3617单药或联合化疗、贝伐单抗治疗晚期实体肿瘤, objectType=article, longId=141954, objectId=0ac1141954e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0ac1141954e7, replyNumber=0, likeNumber=51, createdTime=2019-03-29, rootId=0, userName=30397616, userId=333936755048, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0ac1141954e7, moduleTitle=CLIN CANCER RES：MEDI3617单药或联合化疗、贝伐单抗治疗晚期实体肿瘤, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=0ac1141954e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1754573, encodeId=90d51e54573e0, content=<a href='/topic/show?id=627a5982254' target=_blank style='color:#2F92EE;'>#晚期实体肿瘤#</a>, objectTitle=CLIN CANCER RES：M7824治疗晚期实体肿瘤, objectType=article, longId=133046, objectId=a115133046ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a115133046ba, replyNumber=0, likeNumber=63, createdTime=2018-07-13, rootId=0, userName=30397616, userId=333936755048, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a115133046ba, moduleTitle=CLIN CANCER RES：M7824治疗晚期实体肿瘤, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=a115133046ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1754572, encodeId=59161e54572b7, content=<a href='/topic/show?id=627a5982254' target=_blank style='color:#2F92EE;'>#晚期实体肿瘤#</a>, objectTitle=CLIN CANCER RES：NC-6004联合吉西他滨治疗晚期实体肿瘤, objectType=article, longId=125964, objectId=cc3412596479, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cc3412596479, replyNumber=0, likeNumber=59, createdTime=2018-12-05, rootId=0, userName=30397616, userId=333936755048, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cc3412596479, moduleTitle=CLIN CANCER RES：NC-6004联合吉西他滨治疗晚期实体肿瘤, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=cc3412596479)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1754574, encodeId=1e281e54574f7, content=<a href='/topic/show?id=627a5982254' target=_blank style='color:#2F92EE;'>#晚期实体肿瘤#</a>, objectTitle=CLIN CANCER RES：重组人IL15治疗晚期实体肿瘤, objectType=article, longId=135496, objectId=021613549625, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=021613549625, replyNumber=0, likeNumber=63, createdTime=2018-12-13, rootId=0, userName=30397616, userId=333936755048, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=021613549625, moduleTitle=CLIN CANCER RES：重组人IL15治疗晚期实体肿瘤, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=021613549625)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1754576, encodeId=c05f1e5457637, content=<a href='/topic/show?id=627a5982254' target=_blank style='color:#2F92EE;'>#晚期实体肿瘤#</a>, objectTitle=JCO：Birabresib治疗晚期实体肿瘤, objectType=article, longId=138005, objectId=bc78138005c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bc78138005c1, replyNumber=0, likeNumber=54, createdTime=2018-12-22, rootId=0, userName=30397616, userId=333936755048, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bc78138005c1, moduleTitle=JCO：Birabresib治疗晚期实体肿瘤, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=bc78138005c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1754575, encodeId=881c1e5457599, content=<a href='/topic/show?id=627a5982254' target=_blank style='color:#2F92EE;'>#晚期实体肿瘤#</a>, objectTitle=CLIN CANCER RES：Vanucizumab单药治疗晚期实体肿瘤, objectType=article, longId=135500, objectId=5866135500ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5866135500ab, replyNumber=0, likeNumber=43, createdTime=2018-06-07, rootId=0, userName=30397616, userId=333936755048, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5866135500ab, moduleTitle=CLIN CANCER RES：Vanucizumab单药治疗晚期实体肿瘤, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=5866135500ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1754570, encodeId=d6ab1e545700c, content=<a href='/topic/show?id=627a5982254' target=_blank style='color:#2F92EE;'>#晚期实体肿瘤#</a>, objectTitle=CLIN CANCER RES：IDO1口服抑制剂治疗晚期实体肿瘤, objectType=article, longId=104994, objectId=4b3b104994b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4b3b104994b6, replyNumber=0, likeNumber=70, createdTime=2018-06-21, rootId=0, userName=30397616, userId=333936755048, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4b3b104994b6, moduleTitle=CLIN CANCER RES：IDO1口服抑制剂治疗晚期实体肿瘤, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=4b3b104994b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1754571, encodeId=bc2b1e545712a, content=<a href='/topic/show?id=627a5982254' target=_blank style='color:#2F92EE;'>#晚期实体肿瘤#</a>, objectTitle=CLIN CANCER RES：ABC294640治疗晚期实体肿瘤患者的Ⅰ期临床试验结果, objectType=article, longId=110765, objectId=c218110e6568, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c218110e6568, replyNumber=0, likeNumber=62, createdTime=2018-05-07, rootId=0, userName=30397616, userId=333936755048, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c218110e6568, moduleTitle=CLIN CANCER RES：ABC294640治疗晚期实体肿瘤患者的Ⅰ期临床试验结果, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=c218110e6568)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] williamhill asia 话题小助手

晚期实体肿瘤

2020-05-29

30397616 (审核中...)

前往app查看评论内容

#晚期实体肿瘤#

Front Oncol：安罗替尼联合PD-1抑制剂治疗晚期实体肿瘤有效且毒性可控

2022-04-28

30397616 (审核中...)

前往app查看评论内容

#晚期实体肿瘤#

Clin Cancer Res：PI3K/mTORC1/2双重抑制剂Gedatolisib联合卡铂和紫杉醇治疗晚期实体肿瘤

2021-12-01

30397616 (审核中...)

前往app查看评论内容

#晚期实体肿瘤#

Clin Cancer Res：Wee1抑制剂Adavosertib(AZD1775)在晚期实体肿瘤患者中的抗肿瘤活性及相关生物标志物

2021-09-05

30397616 (审核中...)

前往app查看评论内容

#晚期实体肿瘤#

Clin cancer res：抗肿瘤坏死因子受体抗体MK-4166治疗晚期实体肿瘤的首次临床试验结果

2021-06-11

30397616 (审核中...)

前往app查看评论内容

#晚期实体肿瘤#

Brit J Cancer：mTORC1/2抑制剂sapanisertib 在肾癌、子宫内膜癌或膀胱癌扩张期晚期实体肿瘤的一期研究

2021-08-27

30397616 (审核中...)

前往app查看评论内容

#晚期实体肿瘤#

JAMA Oncol：BMS-986156单药或联合纳武单抗治疗晚期实体肿瘤

2019-12-18

30397616 (审核中...)

前往app查看评论内容

#晚期实体肿瘤#

Lancet oncol：Pegilodecakin联合抗PD-1单克隆抗体是否可为晚期实体肿瘤提供新的治疗机会？

2019-10-16

30397616 (审核中...)

前往app查看评论内容

#晚期实体肿瘤#

CLIN CANCER RES：MEDI3617单药或联合化疗、贝伐单抗治疗晚期实体肿瘤

2019-03-29

30397616 (审核中...)

前往app查看评论内容

#晚期实体肿瘤#

CLIN CANCER RES：M7824治疗晚期实体肿瘤

2018-07-13

30397616 (审核中...)

前往app查看评论内容

#晚期实体肿瘤#

CLIN CANCER RES：NC-6004联合吉西他滨治疗晚期实体肿瘤

2018-12-05

30397616 (审核中...)

前往app查看评论内容

#晚期实体肿瘤#

CLIN CANCER RES：重组人IL15治疗晚期实体肿瘤

2018-12-13

30397616 (审核中...)

前往app查看评论内容

#晚期实体肿瘤#

JCO：Birabresib治疗晚期实体肿瘤

2018-12-22

30397616 (审核中...)

前往app查看评论内容

#晚期实体肿瘤#

CLIN CANCER RES：Vanucizumab单药治疗晚期实体肿瘤

2018-06-07

30397616 (审核中...)

前往app查看评论内容

#晚期实体肿瘤#

CLIN CANCER RES：IDO1口服抑制剂治疗晚期实体肿瘤

2018-06-21

30397616 (审核中...)

前往app查看评论内容

#晚期实体肿瘤#

CLIN CANCER RES：ABC294640治疗晚期实体肿瘤患者的Ⅰ期临床试验结果

2018-05-07

科室
- - 订阅+
  - 更多科室
工具
服务